Recent Publications by CFE Educators
Recent Published articles, books, and other scholarship by Academy members, CFE Education Scientists, and CFE Faculty.
Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
2023
Authors: Guan T, Laguna A, Soares A, Legasto CS, Block S, Saunders IM, Alvarez K, Pon T, Patel N, Mahajan A, Lee A
BACKGROUND
Direct oral anticoagulant (DOAC) use in cancer-associated venous thromboembolism (CA-VTE) has increased due to updates in recent guidelines and literature. However, select guidelines caution against DOAC use in patients with gastrointestinal (GI) malignancies due to reported increased bleeding events. The objective of this study was to compare the safety and effectiveness of DOACs versus low-molecular-weight heparins (LMWHs) for CA-VTE treatment in patients with GI malignancies.
PATIENTS AND METHODS
This multicenter, retrospective cohort study included patients with primary GI malignancies who received therapeutic anticoagulation with a DOAC or LMWH for CA-VTE between January 1, 2018, and December 31, 2019. The primary outcome was the incidence rate of bleeding events (major, clinically relevant non-major, or minor bleeding events) within a 12-month period following the initiation of therapeutic anticoagulation. The secondary endpoint was the incidence rate of recurrent VTE events within a 12-month period following the start of therapeutic anticoagulation.
RESULTS
After screening, 141 patients met inclusion criteria. The incidence rate of all bleeding events significantly differed between DOAC (4.98 events/100 person-months) and LWMH (10.2 events/100 person-months) recipients. The corresponding incidence rate ratio (IRR) with the DOAC group serving as the reference was 2.05 (p = 0.01), with the majority of bleeds in both groups presenting as minor bleeds. No difference was found between the incidence rate of recurrent VTE within a 12-month period of starting therapeutic anticoagulation between groups (IRR 3.08, p = 0.06).
CONCLUSION
Our results suggest that DOACs do not pose an additional bleeding risk compared to LMWH in patients with certain GI malignancies. Careful selection of DOAC therapy with respect to bleeding risk is still warranted.
View on PubMedAn evaluation of maxillary expansion after Phase I orthodontic treatment with clear aligners using model analysis and cone-beam computed tomography.
2023
Authors: Kevin Yoshiori Kai, Ronnel Azizollahi, Snehlata Oberoi, Andrew Jheon, Mona Bajestan
Diabetes mellitus and risk of breast cancer: a large-scale, prospective, population-based study.
2023
Authors: Xiong F, Wang J, Nierenberg JL, Van Blarigan EL, Kenfield SA, Chan JM, Schmajuk G, Huang CY, Graff RE
BACKGROUND
The objective of this study was to evaluate associations of diabetes overall, type 1 diabetes (T1D), and type 2 diabetes (T2D) with breast cancer (BCa) risk.
METHODS
We included 250,312 women aged 40-69 years between 2006 and 2010 from the UK Biobank cohort. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) were calculated for associations of diabetes and its two major types with the time from enrollment to incident BCa.
RESULTS
We identified 8182 BCa cases during a median follow-up of 11.1 years. We found no overall association between diabetes and BCa risk (aHR = 1.02, 95% CI = 0.92-1.14). When accounting for diabetes subtype, women with T1D had a higher risk of BCa than women without diabetes (aHR = 1.52, 95% CI = 1.03-2.23). T2D was not associated with BCa risk overall (aHR = 1.00, 95% CI = 0.90-1.12). However, there was a significantly increased risk of BCa in the short time window after T2D diagnosis.
CONCLUSIONS
Though we did not find an association between diabetes and BCa risk overall, an increased risk of BCa was observed shortly after T2D diagnosis. In addition, our data suggest that women with T1D may have an increased risk of BCa.
View on PubMedDemonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV.
2023
Authors: Gandhi M, Hickey M, Imbert E, Grochowski J, Mayorga-Munoz F, Szumowski JD, Oskarsson J, Shiels M, Sauceda J, Salazar J, Dilworth S, Nguyen JQ, Glidden DV, Havlir DV, Christopoulos KA
Long-term complications and health-related quality of life outcomes after radical prostatectomy with or without subsequent radiation treatment for prostate cancer.
2023
Authors: Baskin A, Cowan JE, Braun A, Lonergan PE, Mohamad O, Washington SL, Zhao S, Broering JM, Cooperberg MR, Breyer BN, Carroll PR
Association of Language Barriers With Perioperative and Surgical Outcomes: A Systematic Review.
2023
Authors: Joo H, Fernández A, Wick EC, Moreno Lepe G, Manuel SP
Immunoassay Detects Salivary Anti-SSA/Ro-52 Autoantibodies in Seronegative Patients with Primary Sjögren's Syndrome.
2023
Authors: Kamounah S, Tayob N, Chiang S, Wei F, Park JK, Kwon HM, Feng Z, Chia D, Pedersen AML, Song YW, Wong DTW
Healthcare Disparities in Orthopaedic Surgery: A Comparison of Anterior Cruciate Ligament Reconstruction Incidence Proportions With US Census-Derived Demographics.
2023
Authors: Solarczyk JK, Roberts HJ, Wong SE, Ward DT
Rapid and sustained contact tracing training for COVID-19 in San Francisco: a training model for developing an emergency public health workforce.
2023
Authors: Martin S, Kalra A, Jenny A, Maher AD, Foreman A, Chavez A, Gagliano J, Reid MJA, Brickley DB
Designing and developing a digital equity dashboard for the emergency department.
2023
Authors: Yi S, Burke C, Reilly A, Straube S, Graterol J, Peabody CR
